Clinical Trials Evaluating the Efficacy of Venetoclax
Venetoclax Monotherapy
Venetoclax has been trialed as monotherapy in the relapsed/refractory (R/R) setting, showing a 79% response rate among patients with R/R CLL or small lymphocytic lymphoma (SLL). High-risk populations, including those with del17p, del11q, and unmutated IGHV, also showed similar responses. The 15-month progression-free survival (PFS) was 69% for patients receiving the 400 mg dose. Tumor lysis syndrome (TLS) was a concern initially, but extended ramp-up schedules have mitigated this risk.
Venetoclax with Anti-CD20 Monoclonal Antibodies
Combining Venetoclax with rituximab has shown to improve PFS and OS, with an 86% response rate and 51% achieving a complete response in a phase Ib study. The landmark phase III MURANO trial further confirmed the benefits of this combination, with significantly higher 2-year PFS rates compared to bendamustine plus rituximab.
Venetoclax with Bruton’s Tyrosine Kinase Inhibitors
The combination of Venetoclax with ibrutinib, a BTK inhibitor, offers an all-oral regimen that has shown deep, durable remissions, allowing for a treatment-free interval. The GLOW study highlighted the superiority of this combination over chlorambucil plus obinutuzumab in elderly unfit patients.
Venetoclax in High-risk Patient Populations
Venetoclax-based therapies have provided improved outcomes for patients with high-risk disease markers such as del(17p), TP53 mutations, and unmutated IGHV, compared to chemoimmunotherapy. However, these patients still have worse outcomes than their non-high-risk counterparts.
Measurable Residual Disease Guided Treatment Duration
MRD assessments are becoming increasingly important in CLL treatment, with Venetoclax-based regimens achieving undetectable MRD (uMRD) in a significant proportion of patients. This has implications for treatment duration and the potential for treatment-free intervals.
Re-challenge of Venetoclax Therapy
Small studies suggest that Venetoclax can induce responses upon re-initiation in relapsed patients, with a median PFS of 25 months after retreatment. Ongoing trials are expected to provide more robust data on the efficacy of Venetoclax retreatment.
Expert Opinion
Venetoclax has established itself as an effective treatment for inducing deep responses in CLL, with ongoing debates and trials comparing it to BTK inhibitors. The role of MRD status in guiding treatment decisions and the potential for treatment-free intervals are areas of active research. The future of CLL treatment looks promising, with ongoing trials exploring various combinations and durations of therapy to optimize patient outcomes.
